Unleashing the Power of Tregs

Multiple Treg therapeutic modalities addressing neurodegenerative, autoimmune, and metabolic diseases

We are a clinical-stage company focused on developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Strong proof of concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s

Treg Enhancing Biologics:

Treg Enhancing
Biologics:
Allogeneic Treg
Derived Exosomes:
Autologous Treg
Cell Therapy:

Video

News

Keep up-to-date with the latest news about Coya Therapeutics

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)

May 20, 2024

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function,...

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

May 09, 2024

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function,...

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Apr 26, 2024

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function,...

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Apr 22, 2024

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function,...

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Apr 18, 2024

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function,...

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Apr 08, 2024

Dr. Appel previously presented 4-HNE biomarker data in March 2024 at the Society of Neuroimmune Pharmacology Conference showing high correlation (91.7% sensitivity and 71.1% specificity)